BELGRADE, SERBIA, March 31 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) www.htdsmedical.com - The "Best Technological Innovation Award" is a most coveted, prestigious award, and is announced annually by the Serbian Ministry of Science and Technological Development. Submitted with the award application, HTDS included extremely encouraging results from the preliminary trial of their Ribavirin product, confirming its combative effective against glial scarring.
HTDS Chief Scientist, Dr. Sanja Pekovic was elected as an expert to represent Serbia in the COST (European Cooperation In The Field of Scientific And Technical Research) Action B30: Neural Regeneration and Plasticity. Meetings are scheduled twice a year.
Recently, HTDS - IBISS GROUP competed for the European Collaborative Project (FP7). Dr. Pekovic said "We are delighted to have successfully passed the first level of selection. HTDS is looking forward to another great year." Final results will be released sometime in 2009.
The company will provide further details as they become available.
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved